Susan L. Slager, PhD, discusses some of the recommendations for genetic testing in individuals with a family history of chronic lymphocytic leukemia.
Susan L. Slager, PhD, endowed professor of lymphoma research at Mayo Clinic, discusses some of the recommendations for genetic testing in individuals with a family history of chronic lymphocytic leukemia (CLL).
While genetic testing can identify inherited variants associated with CLL risk, there are currently no preventive strategies available to mitigate these risks. In this interview, Slager highlights the importance of individualizing the decision to undergo genetic testing.
She explains that while some individuals may find the information valuable, others may prefer to avoid potential anxiety or distress. Further, Slager emphasizes the need for careful consideration and discussion with a healthcare provider prior to proceeding with genetic testing.
In addition to her recommendations, Slager emphasizes her interest in identifying factors that contribute to disease progression and in developing strategies to prevent or delay the onset of CLL.
Transcription:
0:09 | You can get genetic testing, but there is nothing that you can do about it yet and there are no preventive strategies. You can find that you have this genetic score, and you are on the high end, and you have a family history of CLL or lymphoma, but there is nothing you can do about it right at the moment. So, when I talk to the general population and ask the question, “Would you want to know?” it varies by individual. Some people say they do want to know and just be more informed and other people say they are not interested. I think it is still an individualized process. But as far as clinically, I do not recommend getting it tested, or at least have a conversation [before testing].
0:54 | So, obviously I am more interested in etiology, mostly about the precursors and conditions for monoclonal B-cell lymphocytosis, understanding why people get this precursor condition, and understanding why individuals progress and why a lot of people do not progress. I think that is the active area that excites me.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More